Primer: Akero Therapeutics (AKRO US) - Aug 2026
Akero Therapeutics is a clinical-stage biotechnology company singularly focused on developing its lead candidate, efruxifermin (EFX), for the...
98 Views
Biopharma Week in Review MFN Fears Overdone but Medicare Negotiation Changes Reapplied Pressure
President Trump’s MFN executive order lacked a clear plan to lower drug prices, with any immediate moves likely facing legal challenges.
299 Views
No more insights